

# Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

|                               |                |
|-------------------------------|----------------|
| Name of entity                | ABN/ARSN       |
| Sigma Pharmaceuticals Limited | 15 088 417 403 |

We (the entity) give ASX the following information.

### Information about buy-back

|   |                                   |  |
|---|-----------------------------------|--|
| 1 | Type of buy-back                  | On-market buy-back   |
| 2 | Date Appendix 3C was given to ASX | 13 September 2012<br>(Associated Appendix 3D dated 18 November 2015) |

### Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

|   | Before previous day  | Previous day             |
|---|--|--------------------------|
| 3 | Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received | 111,721,420<br>50,000    |
| 4 | Total consideration paid or payable for the shares/units   | \$81,449,527<br>\$39,945 |

**Appendix 3E**  
**Daily share buy-back notice**

| <b>Before previous day</b> | <b>Previous day</b> |
|----------------------------|---------------------|
|----------------------------|---------------------|

|  |   |  |
|--|---|--|
| 5 If buy-back is an on-market buy-back | Highest price paid: \$0.8700<br><br>Lowest price paid: \$0.5600 | Highest price paid: \$0.8025<br><br>Lowest price paid: \$0.7950<br><br>Highest price allowed under rule 7.33: \$0.8642 |
|--|---|--|

**How many shares/units may still be bought back?**

|   |           |
|---|-----------|
| 6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back | 6,858,932 |
|---|-----------|

**Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here: \_\_\_\_\_  
 (Director/Company secretary)

Date: 9 December 2015

Print name: JEFF SELLS

== == == == ==